Midway Research Center

What Midway Research Center does

Midway Research Center is a non-profit, private clinical research facility headquartered in Fort Pierce, Florida, founded in 2012 by Dr. Moti Ramgopal, MD, FACP, FIDSA. The organization conducts Phase I through Phase IV clinical trials with a primary focus on infectious diseases, particularly HIV, Hepatitis C (HCV), HPV, and related sexually transmitted infections. According to company disclosures, the center has completed more than 250 clinical trials, served more than 500 patients, and delivered over $5 million in free medical care to eligible participants, including involvement in studies of every new HIV treatment drug entering the market in the past decade.

The center's service portfolio spans five core offerings: clinical trial services, HIV research studies, HPV and anal dysplasia treatment (including Infrared Coagulation procedures), STD testing and treatment, and lipodystrophy management. Pharmaceutical sponsors — including Gilead Sciences, AbbVie, Janssen, ViiV Healthcare, GlaxoSmithKline, CytoDyn, Allergan, Actelion, Taimed Biologics, and AiCuris — fund studies conducted at the Fort Pierce site, with the center operating as a contract research site rather than as a sponsor. All research protocols are reviewed and approved by an Institutional Review Board and the FDA, with the team operating under certified principal investigators and supported by 24+ journal publications.

The go-to-market model is dual-sided: pharmaceutical sponsors are the paying customers providing revenue through study sponsorship fees, while patients are recruited via healthcare provider referrals and community outreach and receive study medications, laboratory testing, and medical treatments at no cost. The organization is affiliated with the 501(c)(3) nonprofit Midway Specialty Care Center (founded in 2014 by Dr. Ramgopal) and Asvins.org, providing a broader care continuum that includes behavioral health, pharmacy, and nutrition services. The center operates with 11-50 employees under founder-led management, without disclosed external institutional investment or institutional funding rounds.

Name

Midway Research Center

Legal name

Midway Research Center

Website

https://midwayresearch.org

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Midway Research Center is a non-profit clinical research facility in Fort Pierce, Florida, founded in 2012 by Dr. Moti Ramgopal. The center conducts Phase I-IV clinical trials focused on HIV, HCV, HPV, and related infectious diseases, sponsored by pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Reference & Esoteric Testing Laboratories (HLAFAMAJ), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Clinical trial services
• Infectious disease research
• HIV clinical trials
• Hepatitis C research
• Pharmaceutical trial site

Headquarters

HQ city

Fort Pierce

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Sponsorships: Midway Research Center conducts clinical trials sponsored by pharmaceutical companies including Gilead Sciences, AbbVie, Janssen, ViiV Healthcare, GlaxoSmithKline, and others. The center provides research services in exchange for sponsorship funding.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Midway Research Center is a clinical trial site that conducts Phase I to Phase IV clinical trials sponsored by pharmaceutical companies, with a focus on HIV, hepatitis C, HPV, STD, and related infectious diseases. Eligible patients receive study drugs, laboratory testing, and medical treatments related to study protocols at no cost. The center has completed more than 250 clinical trials and delivered over $5,000,000 in care to more than 500 patients.

Product overview

Midway Research Center is a multi-disciplinary clinical research facility offering clinical trial services for HIV, HPV, STD, and related infectious diseases. The center operates as a unified clinical research operation, providing patients access to cutting-edge treatments through Phase I to Phase IV clinical trials. Their service portfolio includes HIV research studies, HPV and anal dysplasia treatment, STD testing and treatment, and lipodystrophy management. The organization has completed over 250 clinical trials and provided over $5 million in care to more than 500 patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Services Phase I to Phase IV clinical research services focused on HIV, HPV, STD, and infectious diseases, providing eligible patients access to cutting-edge treatments, study drugs, labs, and medical care at no cost.
• HIV Research Studies

Quantifiable outcome

• More than 500 patients gained access to free and advanced medical treatment
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Gilead SciencescoreStrategic or Co-development PartnerMajor sponsor of multiple HIV, HCV, and other infectious disease clinical trials. Sponsored trials including GS-US-380 series, GS-US-292 series, GS-US-236 series for HIV treatments and various HCV studies.
• AbbViecoreStrategic or Co-development PartnerSponsored clinical trials including hepatitis C treatments (ABT-493/ABT-530), HIV studies (M13 series), and various Phase 2/3 drug development programs.
• JanssencoreStrategic or Co-development PartnerSponsored HIV drug trials including the DIAMOND study evaluating Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) for rapid initiation treatment.
• ViiV HealthcarecoreStrategic or Co-development PartnerSponsored HIV clinical trials including dolutegravir studies and cabotegravir/rilpivirine long-acting injectable trials.
• GlaxoSmithKlinecoreStrategic or Co-development PartnerSponsored various HIV clinical trials including dolutegravir studies and integrase inhibitor research.
• CytoDyncoreStrategic or Co-development PartnerSponsored PRO 140 clinical trials for treatment-experienced HIV patients with CCR5-tropic virus.
• AllerganminorStrategic or Co-development PartnerSponsored Phase 2 osteomyelitis trial comparing dalbavancin versus active comparator.
• ActelionminorStrategic or Co-development PartnerSponsored Phase 3 Clostridium difficile-associated diarrhea study comparing cadazolid versus vancomycin.
• Taimed BiologicsminorStrategic or Co-development PartnerSponsored Phase 3 ibalizumab study for treatment-experienced patients infected with multi-drug resistant HIV-1.
• AiCurisminorStrategic or Co-development PartnerSponsored Phase 2 trial of pritelivir for acyclovir-resistant HSV infections in immunocompromised adults.
• Midway Specialty Care CentercoreStrategic or Co-development PartnerNot-for-profit 501(c)(3) organization founded by Dr. Ramgopal to enhance access to treatment for all patients living with HIV. Provides comprehensive care including behavioral health, pharmacy, and nutrition services.
• Asvins.orgminorStrategic or Co-development PartnerCollaboration of practices founded by Dr. Ramgopal focused on treating all patient needs for better quality of life.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Centricity Research: A clinical trial site network delivering Phase I–IV studies across multiple therapeutic areas. Comparable to Midway in operating model, sponsor relationships, and patient-recruitment-driven execution of community-based trials.
• Accel Research Sites: A network of independent clinical research sites conducting trials across multiple therapeutic areas. Comparable to Midway as a multi-site, community-based clinical trial operator competing for the same sponsor study allocations and patient populations.
• PMG Research: An integrated clinical research site network operating across the U.S. with therapeutic breadth including infectious disease. Directly comparable as a site-based clinical research operator serving biopharma sponsors with Phase I–IV trial execution.
• Velocity Clinical Research: An integrated, multi-site clinical trial site network conducting Phase I–IV studies across therapeutic areas including infectious disease. Directly comparable as a similarly positioned, site-focused research organization that recruits patients and executes sponsor protocols on a fee-for-service basis.
• Headlands Research: A clinical research site organization with multiple locations focused on multi-therapeutic Phase I–IV trials. Comparable to Midway as a site-based research operator serving the same sponsor and patient community.

Broad incumbents

• Medpace: A mid-to-large CRO with deep therapeutic expertise in infectious disease and HIV. Comparable to Midway in conducting HIV and infectious disease trials for biopharma sponsors, but as a full-service CRO with global reach rather than a focused site.
• ICON plc: A global CRO with significant infectious disease and vaccine trial capabilities. Comparable in providing biopharma sponsors with clinical trial execution infrastructure across therapeutic areas including HIV, HCV, and infectious disease.
• IQVIA: A global full-service CRO and clinical research operator that also runs dedicated site networks and site-management services. Comparable to Midway in serving as an execution layer for biopharma-sponsored trials, but at vastly greater scale and breadth.

Emerging players

• AIDS Clinical Trials Group (ACTG) Network Sites: NIH-funded academic and community clinical trial sites conducting HIV and infectious disease research. Comparable to Midway in therapeutic focus on HIV and HCV trials, though operating under academic/NIH sponsorship models rather than direct pharma sponsorship.

Others

• WCG (WIRB-Copernicus Group): A clinical research services company providing IRB review, technology, and site enablement. Comparable to Midway as an enabling participant in the same clinical trial ecosystem — adjacent rather than directly competitive, but serving overlapping sponsors and protocols.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/midwayresearch
• YouTubeyoutube.com/channel/midwayresearch
• Facebookfacebook.com/midwayresearch
• LinkedInlinkedin.com/company/midwayresearch
• Instagraminstagram.com/midwayresearch

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Midway Research Center